Esperion Therapeutics presented new data at the 2026 European Atherosclerosis Society Congress showing bempedoic acid effectively lowers LDL cholesterol in children aged 6-17 with familial hypercholesterolemia and is well tolerated. A secondary analysis from the CLEAR Outcomes study also identified factors like female sex, higher baseline LDL-C, and ezetimibe use that enhance LDL-C reduction in statin-intolerant adults. These findings support bempedoic acid as a safe adjunct or alternative to statins, with ongoing Phase 3 pediatric trials planned. The data reinforce the role of Esperion’s products NEXLETOL and NEXLIZET in managing cholesterol and reducing cardiovascular risk.
Emerson Electric announced a collaboration with Saudi Aramco to co-develop next-generation corrosion management solutions using ultrasonic online monitoring and wireless technology. This partnership aims to improve operational safety and performance ...
Natural Grocers, a leading organic grocery retailer, is opening its first store in Wisconsin on June 10, 2026, in Lake Geneva. The grand opening will feature giveaways, discounts, a prize wheel, and a $2,500 donation to the Lake Geneva Food Pantry, h...
Current inflation trends in the U.S. are often compared to the 1970s stagflation, but experts highlight key differences. Unlike the 1970s, today's inflation is driven mainly by supply-side pressures such as rising commodity prices and geopolitical te...
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, announced it will present at two upcoming investor conferences: William Blair’s Growth Stock Conference on June 2 and Jefferies Global Healthcare Conf...
